Small caps round-up: Omega Diagnostics, Oxford Biomedica, i-design ...

published 16 April 2012

The cash-point marketing company i-design said that revenues for the first half of its current financial year will be ahead of the same period of 2011. The group creates advertising solutions for banks and third parties through cash-point screens. A new contract with a Canadian bank has boosted turnover, with the firm now expecting to turn a small profit-before-tax for the full year.

The share price of medical diagnostics group Omega Diagnostics hit fever pitch after the firm revealed revenue for the year ended March 31st, 2012, is expected to be £11.12m, approximately 41% ahead of last year's result. On a like-for-like basis sales growth is approximately 5%.

Another medical firm, Oxford Biomedica, stormed higher after successfully completing a Phase I/II study of its ProSavin drug for treating patients with mid-stage Parkinson's Disease. The patients receiving the highest dosage of the treatment saw their motor function improve by 30%.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Executive Chairman, Justin Drummond and Non-Executive Directors, Haresh Kanabar and Alessandro Malacart have resigned "with immediate effect to pursue other projects" from leisure and entertainment investment firm Brainspark. The company has had a torrid time of late, dropping 62% this year. Commenting on Drummond's departure the group's Chief Executive Alfredo Villa said: "Justin joined the board in February of this year at a very difficult time for the company, but his contribution during his short tenure, particularly his ability to quickly raise money for us, has left Brainspark in a much stronger position."